Thursday, June 30, 2016 5:04:44 PM
This is a forum, and not an official news media source like Marketwatch
#1 is forward looking, therefore, not a historical event. Please demonstrate, using Generally accepted accounting principles (GAAP) showing how a consulting fee worked into a construction contract will result in actual net profits.
#2. Noone has said that MCIG/or VTCQ would not get royalties for VitaCig branded products sold overseas. Many have questioned whether MCIG will get royalties for VitaStik branded products; due to the VitaStik debacle. In addition, because of MCIG's history of fluffing numbers (i.e., "conservative 7-10 Million" in revenue - which MCIG FAILED to achieve), will always raise questions when one uses "up to 25%".
#3 Rollies is Delayed. That's it. If MCIG can't make their deadlines, then they shouldn't bait new investors and string along existing shareholders with unrealistic deadlines.
Talk is cheap. Actual execution will earn the trust back that MCIG is asking for. MCIG hasn't earned it.
At the end of the day, everything below is speculative as they are forward looking statements.
http://investorshub.advfn.com/boards
/read_msg.aspx?message_id=123634047
To dispel some of the myths being purported on these forums, I will re-clarify what is accurate. Anything else that you hear is speculative...
#1 GreenLeaf has $200,000 in profit minimum (as per the last PR), couple that with a documentary deal. NOTE: One was NOT exchanged for the other, MCIG in FACT gets both.
#2 VitaCig's royalties and revenues (all encompassing) are now going to MCIG. The illegitimate actions of one prior executive does not impact our contracts in both Europe and Asia.
#3 Rollies is a long term revenue line, with multiple aspects to capitalize on different steams, demands, and requirements. No one ever builds a house without laying out a blueprint, its inconceivable, you will not make it past the first inspector. Deployment takes time, and we want this done correctly. Discovering or moving on additional revenue streams while waiting for regulatory approval is a positive thing, not a negative. We will not stop looking for ways to expanding into existing, new, and emerging markets.
I hope this adds some clarity, or answers a few questions. I know that Mr. Hawkins put a lot of effort into addressing these various topics, but it appears that we need to re-explain things due to misinformation being spread here.
